Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs

Executive Summary

Implementer of many drug review changes will leave in January after nearly 32 years of public service.

Advertisement

Related Content

Gottlieb Joins HHS Transition Team; Will Next Stop Be FDA?
US FDA Getting More Money Up Front Under Cures Bill Revisions
Merck R&D Exec Jumps To US FDA As Office Of New Drugs Deputy Director
FDA's Pazdur To Retain Drug Approval Duties In Oncology Center Of Excellence
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
Woodcock’s Passion Project: CDER Chief Shifts Duties To Lead Quality Office
Generic Drugs 2014: OGD Creates Internal Review Goals, May Make OND-Inspired Changes
FDA Generics Office Gets Third Director In Three Workdays; Uhl Brings Policy, Pharmacology Experience
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
BURROUGHS-WELLCOME’s SEMPREX-D ENDORSED FOR SEASONAL ALLERGIC RHINITIS, BUT NOT PERENNIAL, BY FDA ADVISORY CMTE.; LABELING WILL CARRY SEDATION PRECAUTION

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel